Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck ProQuad / M-M-R II / Varivax by Year
ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — U.S. sales ($M) ($M)
Merck ProQuad / M-M-R II / Varivax: $1,885M in FY2025, down 1.8% from a year earlier.
Where the FY2025 figure comes from
“|| ProQuad/M-M-R II/Varivax | 2,451 | 2,485 | -1 | 1,885 | 1,919 | -2 | 566 | 566 | 0”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,885 | -1.8% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 1,919 | +4.5% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 1,837 | +6.6% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 1,724 | +5.8% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 1,629 | +18.2% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 1,378 | -18.1% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 1,683 | +17.7% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 1,430 | +4.1% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 1,374 | +0.9% | Form 10-K (filed 2020-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 1,362 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up proQuad / M-M-R II / Varivax
Cite this data
StockData. (2026). Merck ProQuad / M-M-R II / Varivax ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-proquad-mmr-varivax-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.